Although guidelines for the management of atrial fibrillation advocate for anticoagulation in patients with a high stroke risk (CHA2DS2-VASc score of 2 or greater), the recommendations for patients at low (CHA2DS2-VASc 0) and in particular intermediate (CHA2DS2-VASc 1) risk of stroke are less clear. In this blog, we discuss antithrombotic strategies in these latter two subgroups.
For patients with atrial fibrillation and structural heart disease, antiarrhythmic options remain limited. Although amiodarone has been a cornerstone of drug therapy in this population, dofetilide is a viable option for many patients. In this piece, we review the safety and efficacy of this often-overlooked drug.